Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection.

Trial Profile

Phase I/II Study of PR104 in Subjects With Refractory/Relapsed Acute Leukemia Using Adaptive Dose Selection.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2012

At a glance

  • Drugs PR 104 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 30 Aug 2012 Planned end date changed from 1 Jun 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 15 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
    • 22 Mar 2012 Status changed from active, no longer recruiting to recruiting as reported by M.D. Anderson Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top